A U.K. national health service (NHS) hospital has begun offering Allurion Technologies Inc.’s swallowable gastric balloon to patients struggling to lose weight for surgery. The move is a boon for the company amid rising competition in the weight loss market from GLP-1 agonists.
Researchers from Case Western Reserve University have filed for patent protection for a system and method for treating obesity or other gastric and/or metabolic disorders via closed-loop vagus nerve stimulation.
“Digital therapeutics (DTx) for obesity may seem light years away,” Rhee Sang-youl, of Kyung Hee University Medical Center (KHMC), said to the Korea Society of Cardiology (KSC) 2023 audience members on October 13, “but the reality is that it’s right in front of us.”
Fractyl Health Inc. reported clinical updates on the Revita real world registry in Germany which has demonstrated clinical remission from type 2 diabetes (T2D) employing a device that resurfaces the duodenal mucosa, the innermost layer of the first portion of the small intestine, and a potential root cause of T2D.
Researchers from the Institute of Translational Genomics at Helmholtz Munich have described a genetic overlap between type 2 diabetes (T2D), a disease that is also associated with obesity, and osteoarthritis, a degeneration of the joints that worsens with age and coincides in the factor risk of being overweight. The researchers used genetic data, multiomics and functional analysis of the tissues T2D and osteoarthritis express to identify which genes were associated and correlated with both diseases. They published their results on July 10, 2023, in The American Journal of Human Genetics.
In collaborating with Novo Nordisk A/S, privately held Aspect Biosystems Ltd. entered its biggest ever deal that could bring in more than $2.6 billion while advancing its 3D, bioprinted tissue therapeutics technology. The two companies will collaborate to develop up to four diabetes and/or obesity products, a Novo specialty, using implantable bioprinted tissues to replace, repair or supplement human biological functions. The initial target will be type 1 diabetes.
Metabolic health is at an odd juncture. With the advent of glucagon-like peptide (GLP-1) agonists, pharmacologically induced weight loss has matured into a viable therapeutic option at long last. And research into the drug class is continuing apace.
Teleflex Inc. is going big on its investment in the business of helping people reduce their size with an agreement to acquire Standard Bariatrics Inc. for an upfront cash payment of $170 million with contingent payments of $130 million upon achievement of specified commercial milestones. The companies expect to close the transaction early in the fourth quarter of 2022. Standard Bariatrics produces a novel clamp and staple system for gastric sleeve surgery, the Titan sleeve gastrectomy stapler (SGS).
A study by researchers led by David James from the University of Sydney showcases the diversity in metabolic responses observed across different mouse strains exposed to two different diets that demonstrates the heritability of metabolic traits.
Apollo Endosurgery Inc. presented strong results from its endoscopic sleeve gastroplasty study with patients achieving an excess body weight loss of 49.2% at 12 months and the great majority maintaining that loss for two years. Serious adverse events occurred in 2% of patients and all resolved without intensive care or surgical intervention.